Scott Brunner, CEO of the Alliance for Pharmacy Compounding, explained how compounders filled gaps during drug shortages and provided custom formulations.
Merck’s drug, molnupiravir, was found to reduce hospitalizations and deaths by 30 percent, while Pfizer's antiviral pill had a nearly 90 percent reduction.